Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRABECTEDIN vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
Unresectable or metastatic liposarcoma or leiomyosarcoma after prior anthracycline-containing therapy,Metastatic soft tissue sarcoma (EU)
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
1.5 mg/m² intravenously over 24 hours every 3 weeks.
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal elimination half-life ranges from 26 to 40 hours (mean ~33 hours) in patients with normal hepatic function, allowing for a 3-weekly dosing interval.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
Primarily hepatic via CYP3A4; also a substrate of P-glycoprotein.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily fecal (approximately 58% of administered dose) with minor renal excretion (about 21% as unchanged drug and metabolites). Biliary excretion accounts for a significant portion of elimination via feces.
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
Approximately 97-98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Volume of distribution at steady state is approximately 1000 L (>10 L/kg), indicating extensive tissue distribution and binding.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Not applicable; administered intravenously. Oral bioavailability is negligible due to extensive first-pass metabolism.
Intravenous administration yields 100% bioavailability.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
Contraindicated in patients with severe hepatic impairment (Child-Pugh C). For moderate hepatic impairment (Child-Pugh B), reduce starting dose to 0.9 mg/m². For mild hepatic impairment (Child-Pugh A), no dose adjustment but monitor closely.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and efficacy not established in pediatric patients.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustment recommended based on age alone; monitor renal and hepatic function due to potential age-related decline.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
Trabectedin is associated with severe and fatal neutropenic sepsis, rhabdomyolysis with renal failure, cardiotoxicity (cardiomyopathy, heart failure), hepatotoxicity, and extravasation leading to tissue necrosis. It should only be administered under the supervision of a qualified healthcare provider experienced in the use of antineoplastic agents.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Myelosuppression (neutropenia, thrombocytopenia, anemia), hepatotoxicity (elevated liver enzymes, bilirubin, hepatic failure), cardiotoxicity (LVEF decline, heart failure), rhabdomyolysis, extravasation injury, hypersensitivity reactions, and embryo-fetal toxicity.
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
Hypersensitivity to trabectedin or any of its excipients, concomitant use with yellow fever vaccine, severe hepatic impairment.
None known.
Grapefruit and grapefruit juice should be avoided as they may increase trabectedin levels. There are no other specific dietary restrictions.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
Trabectedin is teratogenic based on animal studies. It is contraindicated in pregnancy. First trimester exposure carries high risk of major malformations and pregnancy loss. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Effective contraception is required during treatment and for at least 3 months after the last dose.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
Unknown if trabectedin is excreted in human milk; however, due to potential serious adverse reactions in breastfeeding infants, women should discontinue breastfeeding during treatment and for at least 3 weeks after the last dose. M/P ratio is not available.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
No clinical data are available for dose adjustments during pregnancy. Trabec... is contraindicated in pregnancy; therefore, no dose adjustment is recommended. If inadvertent exposure occurs, immediate discontinuation and supportive care are advised.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
Trabectedin is a marine-derived alkylating agent indicated for advanced soft tissue sarcoma (STS) and relapsed platinum-sensitive ovarian cancer. It requires dexamethasone premedication to reduce hepatotoxicity. Monitor liver function tests (LFTs) closely; dose reduction or interruption is needed for transaminase elevation. Administer via central line due to vesicant properties. Consider cardiac monitoring as QT prolongation can occur. Use with caution in patients with hepatic impairment.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
This medication is given intravenously over 24 hours through a central line.,You will receive dexamethasone before each infusion to help prevent liver side effects.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe fatigue.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during treatment and for at least 3 months after the last dose.,Do not breastfeed during treatment and for 3 months after the last dose.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
"Trabectedin, a potent anticancer agent, inhibits the cytochrome P450 (CYP) enzyme CYP3A4, which is primarily responsible for the metabolism of cyclosporine. When co-administered, trabectedin decreases the clearance of cyclosporine, leading to significantly elevated cyclosporine blood concentrations. This increased exposure raises the risk of cyclosporine-related toxicities, particularly nephrotoxicity, hepatotoxicity, and immunosuppression-related complications, potentially requiring dose adjustments and close monitoring."
"Nilotinib is primarily metabolized by CYP3A4, and trabectedin is a moderate inhibitor of CYP3A4. Concomitant use may increase nilotinib exposure, leading to elevated plasma concentrations and a higher risk of QT prolongation, torsade de pointes, and sudden cardiac death. This interaction requires cautious monitoring and potential dose adjustment."
"Trabectedin, an alkylating agent used for soft tissue sarcoma, is metabolized primarily by CYP3A4. Posaconazole, a potent CYP3A4 inhibitor, can significantly increase trabectedin exposure by reducing its clearance. This elevated concentration may enhance trabectedin-induced hepatotoxicity and myelosuppression, increasing the risk of severe adverse effects such as elevated liver enzymes and febrile neutropenia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRABECTEDIN vs COLUMVI, answered by our medical review team.
TRABECTEDIN is a Antineoplastic Agent that works by Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRABECTEDIN and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRABECTEDIN is: 1.5 mg/m² intravenously over 24 hours every 3 weeks.. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRABECTEDIN and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRABECTEDIN is classified as Category C. Trabectedin is teratogenic based on animal studies. It is contraindicated in pregnancy. First trimester exposure carries high risk of major malformations and pregnancy loss. Second. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.